MediciNova Offers Data From SPRINT-MS Phase 2b Trial Of MN-166 In Progressive MS: For Primary Endpoint, Showed Statistically Significant 48% Reduction In Rate Of Progression, Secondary Endpoint Showed 80% Reduction